ENFN Quote, Financials, Valuation and Earnings

Castellum has a net margin of 2.77% compared to Enfusion's net margin of -11.03%. Enfusion's return on equity of 3.97% beat Castellum's return on equity of -74.03%.

Enfusion has a consensus price target of --, signalling downside risk potential of -9.58%. On the other hand Castellum has an analysts' consensus of -- which suggests that it could grow by 91.83%. Given that Castellum has higher upside potential than Enfusion, analysts believe Castellum is more attractive than Enfusion.

Enfusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Castellum has a beta of -0.960, suggesting its less volatile than the S&P 500 by 195.959%.

Enfusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Castellum offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enfusion pays -- of its earnings as a dividend. Castellum pays out -0.66% of its earnings as a dividend.

Enfusion quarterly revenues are $51.2M, which are larger than Castellum quarterly revenues of $11.6M. Enfusion's net income of $1.4M is higher than Castellum's net income of -$1.3M. Notably, Enfusion's price-to-earnings ratio is 265.75x while Castellum's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enfusion is 6.47x versus 0.72x for Castellum. Usually stocks with elevated PS ratios are considered overvalued.

DigitalOcean Holdings has a net margin of 2.77% compared to Enfusion's net margin of 16.6%. Enfusion's return on equity of 3.97% beat DigitalOcean Holdings's return on equity of --.

Enfusion has a consensus price target of --, signalling downside risk potential of -9.58%. On the other hand DigitalOcean Holdings has an analysts' consensus of $40.73 which suggests that it could grow by 14.08%. Given that DigitalOcean Holdings has higher upside potential than Enfusion, analysts believe DigitalOcean Holdings is more attractive than Enfusion.

Enfusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DigitalOcean Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Enfusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DigitalOcean Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enfusion pays -- of its earnings as a dividend. DigitalOcean Holdings pays out -- of its earnings as a dividend.

Enfusion quarterly revenues are $51.2M, which are smaller than DigitalOcean Holdings quarterly revenues of $198.5M. Enfusion's net income of $1.4M is lower than DigitalOcean Holdings's net income of $32.9M. Notably, Enfusion's price-to-earnings ratio is 265.75x while DigitalOcean Holdings's PE ratio is 42.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enfusion is 6.47x versus 4.51x for DigitalOcean Holdings. Usually stocks with elevated PS ratios are considered overvalued.

F5 has a net margin of 2.77% compared to Enfusion's net margin of 22.14%. Enfusion's return on equity of 3.97% beat F5's return on equity of 19.23%.

Enfusion has a consensus price target of --, signalling downside risk potential of -9.58%. On the other hand F5 has an analysts' consensus of $241.19 which suggests that it could fall by -4.41%. Given that Enfusion has more downside risk than F5, analysts believe F5 is more attractive than Enfusion.

Enfusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison F5 has a beta of 1.056, suggesting its more volatile than the S&P 500 by 5.593%.

Enfusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. F5 offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enfusion pays -- of its earnings as a dividend. F5 pays out -- of its earnings as a dividend.

Enfusion quarterly revenues are $51.2M, which are smaller than F5 quarterly revenues of $746.7M. Enfusion's net income of $1.4M is lower than F5's net income of $165.3M. Notably, Enfusion's price-to-earnings ratio is 265.75x while F5's PE ratio is 26.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enfusion is 6.47x versus 5.32x for F5. Usually stocks with elevated PS ratios are considered overvalued.

Klaviyo has a net margin of 2.77% compared to Enfusion's net margin of -0.57%. Enfusion's return on equity of 3.97% beat Klaviyo's return on equity of -4.78%.

Enfusion has a consensus price target of --, signalling downside risk potential of -9.58%. On the other hand Klaviyo has an analysts' consensus of $36.33 which suggests that it could fall by -4.27%. Given that Enfusion has more downside risk than Klaviyo, analysts believe Klaviyo is more attractive than Enfusion.

Enfusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Klaviyo has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Enfusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Klaviyo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enfusion pays -- of its earnings as a dividend. Klaviyo pays out -- of its earnings as a dividend.

Enfusion quarterly revenues are $51.2M, which are smaller than Klaviyo quarterly revenues of $235.1M. Enfusion's net income of $1.4M is higher than Klaviyo's net income of -$1.3M. Notably, Enfusion's price-to-earnings ratio is 265.75x while Klaviyo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enfusion is 6.47x versus 13.36x for Klaviyo. Usually stocks with elevated PS ratios are considered overvalued.